Survival curves showed that metformin use with docetaxel did not improve prostate cancer specific survival or overall survival.
The US Preventive Services Task Force now suggests decisions about PSA testing should be made on an individual basis for men aged 55 to 69.
Study identifies PSADT cut-points that can aid in risk stratification of men with non-metastatic castration-resistant prostate cancer.
Highest vs lowest quartile of vitamin D binding protein associated with 55% lower odds of prostate cancer.
A family history of prostate cancer was not a major determinant of disease progression during active surveillance, according to a systematic review.
Regular aspirin use linked to lower risk of cancer mortality, especially colorectal, breast, and prostate cancer.
Pathologic Gleason scores, positive surgical margin rates, and PSA doubling times differentiate earlier from later biochemical recurrence after radical surgery.
Among men under the age of 65, men who got 3 to 5 hours of sleep per night had a 55% greater risk of dying of prostate cancer than men who got 7 hours of sleep per night.
Patients with longer hospital stays and pre-discharge complications were at increased risk of readmission within 30 days of discharge.
In 2014, 33.9% of men reported that their health care providers failed to communicate the benefits and risks of PSA-based screening, an increase from 2012.
Population-based prostate cancer screening with MRI has a significantly better risk/benefit ratio.
Select intermediate- and high-risk patients had no greater risks of metastases, AS failure, or interventions over a median of 4 years.
Study finds no difference in metastasis-free survival observed after 15 years compared with radiation therapy or radical prostatectomy.
In a study, systematic biopsy detected clinically significant prostate cancer in only 3% of men with negative findings on multiparametic MRI.
Findings from 2 new studies could enable more informed patient counseling about choice of therapy.
Researchers found no evidence of worse cancer outcomes with nerve-sparing surgery.
A population-based study showed no association between total prostate cancer risk and testosterone replacement therapy (TRT).
At 6 months of treatment, bone imaging showed stable disease in 94% of patients with available data, study finds.
In multiparametric magnetic resonance imaging, rectal distension have a negative effect on T2-weighted and diffusion-weighted images.
Men with Gleason score 3 + 4 were 4.65 times more likely to have upgrading than men with an initial Gleason score of 3 + 3 at 3 years.
Clinical or radiologic progression is less likely with abiraterone plus prednisone than cabazitaxel following first-line docetaxel, study finds.
Study finds that PSA and PSAD indicated prostate cancer above Gleason score 6 for white men only.
In a retrospective study, patients lived the longest if they received docetaxel followed by cabazitaxel and then abiraterone or enzalutamide.
In a survey, 3 in 5 urologists in the United States indicated they perform MRI-US guided biopsy in current practice.
From 1995 to 2011, prostate cancer deaths fell by 13.0% among Danish patients diagnosed with low-risk disease.
Study compared PCa patients who underwent surgery or radiation treatment with a matched group of non-cancer controls.
Black patients who met age criteria for PSA screening were 28% more likely to die of their prostate cancer than patients ineligible for screening.
In a study, each 1-unit increment in body mass index was associated with a 16% lower mortality risk.
Cancer-specific mortality rates dropped from 72.8% in 1995 to 55.8% in 2011, according to a Danish study.
Researchers compared targeted prostate biopsy based on biparametric magnetic resonance imaging with standard 12-core systematic biopsy.
Renal and Urology News Articles
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)